ERBB2 and non-small cell lung carcinoma: Several phase II studies have evaluated the activity of T-DM1 in HER2-alterated NSCLC with modest results, with ORRs ranging from 0 to 20% and from 14.3 to 50% in OE HER2- and MUT HER2 NSCLC, respectively [90,91,92,93].